Thử nghiệm thuốc Recombinant Interferon Alpha - 2a điều trị Ung thư máu trắng hairy cell leukemia
Berman E, Heller G, Kempin S, Gee T, Tran LL, Clarkson B.

Bs Trần Lý Lê cùng các đồng nghiệp vơí nghiên cứu thử nghiệm thuốc recombinant interferon alfa-2a ung thư máu (hairy cell leukemia).
Kết quả thử nghiệm cho thấy thuốc recombinant interferon alfa-2a (rIFN-alpha 2a) noí chung có hiệu quả (khoảng 50%) trong việc điều trị ung thư hairy cell leukemia sau khi theo dõi 2 năm.
Blood. 1990 Feb 15;75(4):839-45.
Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a.
Berman E, Heller G, Kempin S, Gee T, Tran LL, Clarkson B.
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Comment in:
Blood. 1990 Jun 15;75(12):2465-7.
Blood. 1990 Sep 1;76(5):1055.
Abstract
Thirty-five evaluable patients with hairy cell leukemia (HCL) were treated with recombinant interferon alfa-2a (rIFN-alpha 2a), given at a dose of 3 X 10(6) units (U) intramuscularly (IM) daily for 6 months followed by 3 X 10(6) U IM three times a week for an additional 18 months in a single institution study. All treatment was stopped after 24 months. Sixty-nine percent of patients achieved a partial response, 11% a minor response, and 3% (one patient) had stable disease. Six patients (17%) did not respond to rIFN-alpha 2a. Two patients (6%) achieved a response but later progressed on treatment. A total of 23 patients completed 2 years of treatment and are evaluable for long-term follow-up at a median of 20 months postcompletion of therapy (range 9 to 32 months). Eleven patients (48%) have had progression of their disease at a median of 10 months (range .5 to 25 months) after treatment was discontinued. Statistical analysis of pretreatment patient characteristics did not reveal any factor(s) associated with a high probability of responding to rIFN-alpha 2a; however, analysis of post-treatment variables measured after 2 years of treatment suggested that a low platelet count was associated with a high rate of disease progression. These findings are compared with other published trials using rIFN-alpha 2b, a similar but not identical rIFN preparation. We conclude that while rIFN-alpha 2a has a high overall response incidence, the rate of disease progression after therapy is discontinued approaches 50%, and that a subset of patients can be identified who are at high risk for recurrence after completing 2 years of treatment.

PMID: 2302457 [PubMed - indexed for MEDLINE]Free Article.
Cảm ơn Bs Trần lý Lê đã gửi Abstract này.

Ly-Le Tran, MD, JD, FCLM
Global Head, Life Cycle Optimization
Novartis Oncology
Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg 105
East Hanover, NJ 07936-1080
USA
Phone: +1 862 7787182 (Direct)
Admin: +1 862 778 3315 (Janice)
Email : lyle.tran@novartis.com